Letter to the Editor
Profile of non-Hodgkin lymphoma: An Indian perspective
DOI: 10.4103/sajc.sajc_60_18

Dear Editor,

Non-Hodgkin lymphoma (NHL) subtype, pattern of presentation as well as patient population, varies with geographical regions. The World Health Organization (WHO) 2016 lymphoma classification clarifies the diagnosis and management of NHL in relation to the stages of lymphomagenesis. It refines the diagnostic criteria to incorporate the expanding genetic/molecular landscape of NHL. In view of comparative data regarding the distribution of NHL subtypes in India is scarce in the literature, we did this retrospective analysis of newly diagnosed patients with NHL treated in a tertiary care center. A total of 390 cases of adult (>18 years) NHL over a period of 27 months (May 1, 2013 and July 31, 2015) were registered in the Department of Medical Oncology at our institute (AIIMS, New Delhi). The individual NHL cases were retrospectively reviewed according to the WHO lymphoma classification 2016 revision, immunophenotypic expression and morphology. B-cell lymphomas formed 347 (89%) whereas T-cell lymphomas formed 43 (11%) of the NHLs. Diffuse large B-cell lymphoma (DLBCL) was the most common subtype which was present in 267 (68.5%) cases. Follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma, small lymphocytic lymphoma, and Burkitt’s lymphoma amounted to 35 (9%), 20 (5%), 9 (2.3%), 5 (1.3%), and 5 (1.3%) of all NHLs cases, respectively. Among the T-cell lymphomas, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) was the most common subtype 15 (3.8%), followed by anaplastic large-cell lymphomas, T-cell lymphoblastic lymphoma, NK/T-cell lymphoma, and angioimmunoblastic T-cell lymphoma which accounted for 9 (2.3%), 7 (1.8%), 5 (1.3%), and 2 (0.5%) of all NHL cases, respectively. Details of all NHL are given in Table 1. The present study of North Indian population shows key differences in the presentation as compared to the developing country and other parts of India. Details of epidemiological studies are summarized in Table 2.

Classifying NHL according to B- and T-cell type has therapeutic and prognostic significance. Epidemiology of the Indian subcontinent is marked different from that of the Western literature in view of marked preponderance of high-grade lymphoma especially DLBCL. In this study, 68.5% patients were DLBCL, which is significantly higher as compared to previous reported study from India and the West. FL and MCL were the second and third most common subtype of B-NHL, and PTCL-NOS is the most common T-cell lymphoma in adult. The younger average age (median 50 years) of our patients is consistent with the pattern seen in most other malignancies in India, due to the effect of a younger population

Table 1: Non-Hodgkin lymphoma subtypes in adults

| Non-Hodgkin lymphoma (n=390) | n (%) |
|------------------------------|-------|
| B-cell lymphoma              |       |
| DLBCL                        | 347 (89) |
| FL                           | 267 (68.5) |
| MCL                          | 35 (9.0) |
| Marginal zone (nodal and extranodal) | 20 (5.0) |
| SLL                          | 9 (2.3) |
| NHL-others (BL, SLVL, PMBCL, etc.) | 11 (2.8) |
| T-cell lymphoma              |       |
| PTCL-NOS                     | 43 (11) |
| ALCL                         | 15 (3.85) |
| T-cell lymphoblastic lymphoma | 9 (2.3) |
| NK/T-cell lymphoma           | 7 (1.8) |
|AITL                         | 5 (1.3) |
| Others                      | 2 (0.75) |
| Others                      | 5 (1.3) |

Table 2: Subtype distribution of lymphoma across India and the west (USA)

| Type of lymphoma (%) | Nimmagadda et al.[2] | Arora et al.[3] | Naresh et al.[4] | Sahni and Desai[5] | SEER database (USA)[6] | Present study |
|----------------------|----------------------|-----------------|-----------------|------------------|-----------------------|---------------|
| DLBCL                | 55                   | 46.85           | 33.8            | 50.2             | 31.67                 | 68.5          |
| FL                   | 11                   | 10.51           | 12.6            | 13.1             | 32.81                 | 9             |
| ALCCL                | 3                    | 5.04            | 4.1             | 4.8              | 1.11                  | 2.3           |
| PTCL                 | 2.7                  | 5.91            | 1.9             | 4.6              | 3.27                  | 3.9           |
| BL                   | 2.5                  | 3.38            | 1.8             | 3.0              | 1.42                  | 1.3           |
| MCL                  | 1.8                  | 1.59            | 3.4             | 2.1              | 2.18                  | 5             |
| Others               | 24*                  | 26.7*           | 36.8*           | 21.2*            | 27.5*                 | 10*           |

*Others includes: Angioimmunoblastic T-cell lymphoma; adult T-cell lymphoma/leukemia; enteropathy-associated T-cell lymphoma; extranodal NK/T-cell lymphoma, nasal type; hairy cell leukemia; hepatosplenic T-cell lymphoma; lymphoplasmacytic lymphoma; nodal marginal zone B-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma; lymphoplasmacytic lymphoma; primary cutaneous CD30-positive lymphoproliferative disorders; splenic marginal zone B-cell lymphoma; mycosis fungoides/Sézary syndrome; PMBCL. Small lymphocytic lymphoma. DLBCL: Diffuse large B-cell lymphoma, FL: Follicular lymphoma, ALCCL: Anaplastic large-cell lymphoma, PTCL-NOS: Peripheral T-cell lymphoma not otherwise specified, BL: Burkitt’s lymphoma, MCL: Mantle-cell lymphoma, CLL/SLL: Chronic lymphocytic leukemia/small lymphocytic lymphoma, NK: Natural killer, PMBCL: Primary mediastinal B-cell lymphoma

(Continue on page 166...)
pyramid in our country. The present study of North Indian population shows key differences in the NHL subtypes as compared to the developed world and other parts of India.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Ajay Gogia, Chandan K. Das, Lalit Kumar, Atul Sharma, M. C. Sharma¹, Soumya Mallick¹
Departments of Medical Oncology and ¹Pathology, All India Institute of Medical Sciences, New Delhi, India

References
1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 2016;6:643-569.
2. Nimmagadda RB, Digumarti R, Nair R, Bhurani D, Raina V, Aggarwal S, et al. Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India. Indian J Med Paediatr Oncol 2013;34:299-304.
3. Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: Analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013:54:1004-11.
Dear Editor,

We report a case of chronic myeloid leukemia on dasatinib treatment. Isolated central nervous system blast crisis in a patient with chronic myeloid leukemia treated with dasatinib is unusual. The patient was a 57-year-old female with a history of chronic myeloid leukemia in chronic phase. She presented with headache, blurred vision, and confusion. Initial blood investigations, BM aspiration, and biopsy revealed acute lymphoblastic leukemia. The patient was shifted to ICU in view of respiratory distress and found to have subarachnoid hemorrhage, and arterial blood gas showed severe hypoxia and respiratory acidosis; the patient died thereafter.

References

1. Das CH, Gogia A, Kumar L, Sharma A, Sharma MC, Mallick SR, et al. Follicular lymphoma: A North Indian tertiary care centre experience. Asian Pac J Cancer Prev 2018;19:995-8.
2. Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin’s lymphoma in India. Oncology 2016;91 Suppl 1:18-25.
3. Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin’s lymphoma in India: A study of 2773 lymphomas using R.E.A.L. and WHO classifications. Ann Oncol 2000;11 Suppl 1:63-7.
4. Sahni CS, Desai SB. Distribution and clinicopathologic characteristics of non-Hodgkin’s lymphoma in India: A study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma 2007;48:122-33.
5. Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin’s lymphoma in India. Oncology 2016;91 Suppl 1:18-25.
6. Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin’s lymphoma in India: A study of 2773 lymphomas using R.E.A.L.
7. Sahni CS, Desai SB. Distribution and clinicopathologic characteristics of non-Hodgkin’s lymphoma in India: A study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma 2007;48:122-33.
8. Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin’s lymphoma in India. Oncology 2016;91 Suppl 1:18-25.